Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 185,011 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Puberty, Precocious
Interventions: Lupron (leuprolide acetate); Drug
Lead sponsor: Abbott; Industry
Eligibility: Up to 10 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more

Conditions: Metastatic Prostate Cancer
Interventions: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Denver, Colorado • New Haven, Connecticut + 13 more

Conditions: Anemia
Interventions: Ferrous gluconate 325mg, Nutrition counseling; Dietary Supplement · Behavioral
Lead sponsor: Memorial Blood Centers, Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Marijuana Impairment
Interventions: Medium THC, Placebo THC; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sleep, Sleep Quality, Sleepiness, Daytime, Technology
Interventions: Accurate Sleep Data Feedback, Inflated Sleep Data Feedback, Deflated Sleep Data Feedback, Accurate Sleep Data Feedback + Sleep-related Educational Information; Behavioral
Lead sponsor: NextSense, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Transplant, Post Lung Transplantation
Interventions: Blood Draw, Bronchoscopy; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: green tea extract, quercetin, placebo, therapeutic conventional surgery, laboratory biomarker analysis; Dietary Supplement · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Depressive Disorder, Major
Interventions: Prism Training; Device
Lead sponsor: GrayMatters Health Ltd.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Providence, Rhode Island • Houston, Texas

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions: romidepsin, laboratory biomarker analysis, positron emission tomography; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Commack, New York

Conditions: Neurosurgery
Interventions: Not listed
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Opioid-use Disorder, Tobacco Use Disorder
Interventions: Theta Burst Stimulation, Sham TMS; Device
Lead sponsor: Gopalkumar Rakesh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Esophageal Reflux, Barrett Esophagus
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenomatous Polyposis Coli
Interventions: JNJ-64251330; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Spontaneous Bacterial Peritonitis
Interventions: Dextran 70, human albumin; Drug · Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Head and Neck Carcinoma
Interventions: LORETA Neurofeedback Training, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3, Bladder Cancer TNM Staging Primary Tumor (T) T3A, Bladder Cancer TNM Staging Primary Tumor (T) T3B, Bladder Cancer TNM Staging Regional Lymph Node (N) N0, Bladder Cancer TNM Staging Regional Lymph Node (N) N1, Bladder Cancer TNM Staging Distant Metastasis (M) M0
Interventions: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]; Drug
Lead sponsor: Taris Biomedical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 6
States / cities: Hinsdale, Illinois • Rochester, New York • Durham, North Carolina + 3 more

Conditions: AML
Interventions: Azacitidine, APG1252; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Nasotracheal Intubation, Nasal Bleeding
Interventions: Nasotracheal intubation over a bougie, Conventional Nasotracheal Intubation; Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 8 Years to 99 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Psychiatric Disorder
Interventions: Pharmacogentic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Spinal Cord Injuries
Interventions: Hybrid Assistive Limb (HAL); Device
Lead sponsor: Brooks Rehabilitation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Urothelial Cancer
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 89 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study of Lupron Depot In The Treatment of Central Precocious Puberty

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Iron Depletion and Replacement in Blood Donors

Standardized Field Test for Marijuana Impairment II

Nextsense Brain-sensing Buds Study

CLAD Phenotype Specific Risk Factors and Mechanisms

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Correlation of PaCO2 to the Inspired and Expired Oxygen Gradient

Use Of Indocyanine Green In Pancreas Surgery

Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder

Histology Post-Endoscopic Eradication Therapy (EET)

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis

Neurofeedback in Decreasing Acute Radiotherapy-Induced Pain in Patients With Head and Neck Cancer

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Nasotracheal Intubation Over a Bougie

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

Walking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics

Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer